Part D results
CMS's year-end Part D reconciliation, 2022–2024. When a plan's actual drug costs land well above its bid, CMS shares the loss through risk sharing (the "risk corridors"); when they land well below, the plan pays CMS back. A large positive amount means the plan's drug bid was badly underpriced. 2024 is the latest year CMS has published.
How to read this
Risk sharing: positive = CMS paid the plan (costs ran over the bid by more than the corridor); negative = the plan paid CMS. These are CMS's settled figures. Plans also report risk sharing in their MLR filings, sometimes as an estimate made before CMS settled, so a filing can differ.
Per member per year: risk sharing ÷ Part D member-months × 12. Part D member-months include stand-alone drug plan (PDP) members.
CMS's reconciliation also settles reinsurance (catastrophic drug costs) and low-income cost sharing; those are pass-through subsidies, not a sign of profit or loss, so they're shown on contract pages only.
| 2024 | 2023 | 2022 | 3-year total | Per member per year2024 | Part D members2024 avg | |
|---|---|---|---|---|---|---|
| H2459 UCare | $12.1M | $4.4M | $1.9M | $18.3M | $130 | 93,090 |
| H2456 UCare's MSHO | $5.1M | $0 | $102K | $5.2M | $294 | 17,174 |
| H8070 UCare | $3.4M | $119K | — | $3.6M | $158 | 21,714 |
| H5937 UCare | $907K | $0 | $82.1K | $989K | $98 | 9,295 |
| H8783 UCare | $463K | $85.5K | −$8.6K | $540K | $212 | 2,187 |
| H0422 UCare | $108K | −$10.8K | $39.4K | $137K | $170 | 636 |
Red = CMS paid the plan. Sorted by the 3-year total. Parent totals add up each contract under its current parent; CMS also publishes its own parent rollup, which can differ where contracts changed hands.